随着GLP-1类药物持续重塑肥胖症和糖尿病的治疗格局，研究人员也在探讨这些药物是否会影响癌症风险和预后。
As GLP-1 medications continue reshaping the treatment of obesity and diabetes, researchers are also investigating whether the drugs could influence cancer risk and outcomes.
美国癌症研究协会（AACR）本月早些时候发布的《2026年癌症进展报告》指出，肥胖是多种癌症的主要风险因素。
The American Association for Cancer Research's 2026 Cancer Progress Report, released earlier this month, noted that obesity is a major risk factor for many cancers.
由于胰高血糖素样肽-1类药物——包括司美格鲁肽类药物如Ozempic（奥西金）和Wegovy（维高泰），以及替尔泊肽类药物如Mounjaro（莫捷诺）和Zepbound（泽普邦）——已知能导致显著减重并改善代谢健康，因此引起了癌症研究人员的极大关注。
As glucagon-like peptide-1 medications – including semaglutides like Ozempic and Wegovy, and tirzepatides like Mounjaro and Zepbound – are known to cause substantial weight loss and improve metabolic health, they have attracted significant interest among cancer researchers.
热门减肥药或有助预防致命疾病，医生称 虽然AACR报告引用了研究表明GLP-1类药物可能降低某些癌症的风险，但报告强调总体证据好坏参半，仍需更多研究。
POPULAR WEIGHT-LOSS DRUGS MAY HELP PROTECT AGAINST A DEADLY DISEASE, DOCTOR SAYS While the AACR report cited studies suggesting GLP-1 medications may reduce the risk of certain cancers, it emphasized that the overall evidence is mixed and more research is needed.
报告指出：“随机临床试验仍是金标准……然而，此类试验尚未专门针对评估GLP-1受体激动剂使用相关的癌症预后而开展。”
"Randomized clinical trials remain the gold standard ... however, such trials have not yet been conducted specifically to assess cancer outcomes associated with GLP-1 RA use," the report stated.
纽约州布法罗市Roswell Park综合癌症中心胸外科医生Sai Yendamuri重申，肥胖是仅次于吸烟的主要致癌因素。他指出，其他风险因素还包括饮酒和营养不良，“这些都包含在肥胖之中。”“因此，如果肥胖与癌症有关——无论是致癌还是加速癌症进展——合乎逻辑的问题是，一种能减轻肥胖的药物会产生影响吗？”这位未参与AACR报告的医生在接受Fox News Digital采访时表示。
Sai Yendamuri, M.D., a thoracic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York, reiterated that obesity is a leading cause of cancer, second to smoking. Additional risk factors include alcohol and poor nutrition, he noted, "which are all layered into obesity." "So if obesity is related to cancer – both in terms of causing it and increasing its progression – the logical question is, would a drug that decreases obesity have an impact?" the doctor, who was not associated with the AACR report, said in an interview with Fox News Digital.
新研究发现Ozempic类药物与癌症扩散显著减缓有关 Yendamuri表示，有“多方面的证据”表明情况确实如此。
OZEMPIC-STYLE DRUGS LINKED TO MAJOR SLOWDOWN IN CANCER SPREAD, NEW STUDY FINDS There are "many lines of evidence" that suggest this would be the case, Yendamuri suggested.
例如，当研究人员研究接受代谢手术以减轻肥胖的患者时，例如，发现这些患者的癌症发病率下降了。随后，研究人员开始关注使用GLP-1受体激动剂（如Ozempic）的患者。
"For example, when people studied patients who were having metabolic surgery to decrease obesity, for example, the incidence of cancer decreased in those patients." Researchers then started looking at patients who were on GLP-1 receptor agonists, such as Ozempic.
“然后他们将这些患者的癌症发病率与未服用GLP-1受体激动剂的患者进行比较——许多研究发现，服用GLP-1类药物的患者癌症风险较低，生存率较高，”这位医生表示。
"And then they compared the incidence of cancer in those patients to patients who were not taking GLP-1 receptor agonists – and many of those studies found that the risk of cancer was lower and the survival was higher in the patients taking GLP-1s," the doctor said.
奥兹医生将肥胖与慢性疾病激增联系起来，称GLP-1类药物可“启动”更健康的生活 虽然大多数研究显示了这种效果，但Yendamuri指出，一些研究并未发现这种关联——甚至有几项研究显示某些特定癌症（如甲状腺癌）的风险增加。
DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN 'JUMPSTART' BETTER HEALTH Although the majority of studies showed this effect, Yendamuri noted that some did not identify a relationship – and a couple of studies even showed an increased risk of some specific cancers, such as thyroid cancer.
“之所以出现这种差异……是因为这些是回顾性研究，”他说。“也就是说，它们分析现有数据，试图从现有数据中推导关联……但有许多其他变量可能会影响结果。” Yendamuri和他的研究团队开展了自己的研究，探讨肥胖与肺癌的关系。
"The reason you find this disconnect … is because these are retrospective studies," he said. "That is, they look at existing data and they're trying to derive associations from existing data … but there are many other variables that can impact the result." Yendamuri and his team of researchers have conducted their own studies of the relationship between obesity and lung cancer. "We have found in every investigation we've done that obesity does increase the risk of lung cancer," he shared.
“在我们进行的每项调查中，都发现肥胖确实会增加肺癌风险，”他分享道。
"We have found in every investigation we've done that obesity does increase the risk of lung cancer," he shared.
美国癌症治疗延误激增，医生警告体制“需要立即修复” Yendamuri指出，肥胖的定义和测量方式也很关键。虽然身体质量指数（BMI）传统上是标准测量指标，但许多肥胖研究者正逐渐不再单一依赖BMI，转而采用更精确的体脂成分评估方法。Yendamuri分享了其研究的两项关键发现。
CANCER TREATMENT DELAYS SURGE ACROSS US AS DOCTOR WARNS SYSTEM ‘NEEDS FIXING IMMEDIATELY’ Obesity also depends on how it's defined and measured, Yendamuri noted. While body mass index (BMI) has traditionally been the standard measure, many obesity researchers are moving away from relying on BMI alone and instead using more precise assessments of body fat composition. Yendamuri shared two key findings from his research.
“如果有人正在接受切除手术，即肺癌手术，对于正在服用GLP-1受体激动剂的患者，复发率似乎较低。”此外，他指出，处于免疫治疗中且服用GLP-1药物的晚期癌症患者复发率也较低。
"If someone's having a resection, a lung cancer surgery, for patients who are on GLP-1 receptor agonists, the recurrence rate seems to be lower." Additionally, patients with advanced-stage cancers who are in immunotherapy and are taking GLP-1s had lower recurrence rates, he noted.
根据临床前实验室研究，Yendamuri表示，他认为GLP-1药物对癌细胞仅有有限的直接影响。
Based on preclinical laboratory studies, Yendamuri said he believes GLP-1 medications have only a limited direct effect on cancer cells.
点击此处获取更多健康故事 “我们认为发生的情况是，它改变了机体对癌细胞的免疫反应，从而提高了机体对抗癌细胞的能力，”他告诉福克斯新闻数字频道。
CLICK HERE FOR MORE HEALTH STORIES "What we think is happening is that it changes the body’s immune response to cancer cells, and thereby improves its ability to fight cancer cells," he told Fox News Digital.
Yendamuri表示，这种效果可能因癌症类型而异，因为免疫反应在某些癌症中比在其他癌症中更重要。
The effect may differ depending on the type of cancer, Yendamuri said, because the immune response is more important in some cancers than others. "For example, in some cancers like melanoma, we know that the immune response is incredibly important," he said.
“例如，在黑色素瘤等某些癌症中，我们知道免疫反应极其重要，”他说。Yendamuri承认，至少部分抗癌益处可能源于体重减轻。
Yendamuri acknowledged that at least some of the cancer benefit likely stems from weight loss.
测试一下我们最新的生活方式测验 “并非每位服用GLP-1受体激动剂的患者都会出现显著体重减轻，因此在未来的试验中，观察患者获益是否取决于体重减轻将很有意思，”他说。
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ "Not every patient who takes GLP-1 receptor agonists responds with a substantial weight loss, so in future trials, it would be interesting to see if the benefit for patients depends on the weight loss," he said.
“如果服用GLP-1受体激动剂并出现体重减轻的患者，与未出现体重减轻的患者具有相同的抗癌获益，那将回答这个问题。” 点击此处 根据未来试验的结果，该医生表示他希望GLP-1药物终有一天能被视为一种癌症预防机制。
"If those patients who have weight loss with GLP-1 receptor agonists have the same cancer benefit as patients who do not have weight loss, that will answer that question." CLICK HERE TO Depending on the outcomes of future trials, the doctor said he is hopeful that GLP-1 drugs could one day be regarded as a preventive mechanism for cancer.
“我们越来越认识到，除了接受癌症治疗外，生活方式的改变——锻炼、减重，以及现在的GLP-1受体激动剂——都将在增强癌症治疗效果和预防第二原发癌方面发挥作用，”他说。
"More and more, we are realizing that apart from the treatment that you get for cancer, lifestyle modifications – exercise, decreasing weight, and now GLP-1 receptor agonists – will all have a role in both enhancing the treatment of cancer as well as preventing second cancers," he said.
Yendamuri 强调了持续为国家癌症研究所提供资金的重要性，并指出该研究所支持致力于推进癌症研究和开发新发现的研究人员。
Yendamuri emphasized the importance of continued funding for the National Cancer Institute, noting that it supports researchers working to advance cancer research and develop new discoveries.